Antinociceptive mechanisms of orally administered decursinol in the mouse. 2003

Seong-Soo Choi, and Ki-Jung Han, and Jin-Koo Lee, and Han-Kyu Lee, and Eun-Jung Han, and Do-Hoon Kim, and Hong-Won Suh
Department of Pharmacology, College of Medicine, and Institute of Natural Medicine, Hallym University, 1 Okchun-dong, Chunchon, Kangwon Do, 200-702, South Korea.

Antinociceptive profiles of decursinol were examined in ICR mice. Decursinol administered orally (from 5 to 200 mg/kg) showed an antinociceptive effect in a dose-dependent manner as measured by the tail-flick and hot-plate tests. In addition, decursinol attenuated dose-dependently the writhing numbers in the acetic acid-induced writhing test. Moreover, the cumulative response time of nociceptive behaviors induced by an intraplantar formalin injection was reduced by decursinol treatment during the both 1st and 2nd phases in a dose-dependent manner. Furthermore, the cumulative nociceptive response time for intrathecal (i.t.) injection of TNF-alpha (100 pg), IL-1 beta (100 pg), IFN-gamma (100 pg), substance P (0.7 microg) or glutamate (20 microg) was dose-dependently diminished by decursinol. Intraperitoneal (i.p.) pretreatment with yohimbine, methysergide, cyproheptadine, ranitidine, or 3,7-dimethyl-1-propargylxanthine (DMPX) attenuated inhibition of the tail-flick response induced by decursinol. However, naloxone, thioperamide, or 1,3-dipropyl-8-(2-amino-4-chloro-phenyl)-xanthine (PACPX) did not affect inhibition of the tail-flick response induced by decursinol. Our results suggests that decursinol shows an antinociceptive property in various pain models. Furthermore, antinociception of decursinol may be mediated by noradrenergic, serotonergic, adenosine A(2), histamine H(1) and H(2) receptors.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D008297 Male Males
D008784 Methysergide An ergot derivative that is a congener of LYSERGIC ACID DIETHYLAMIDE. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome. Dimethylergometrin,Methylmethylergonovine,Deseril,Desril,Désernil-Sandoz,Methysergide Dimaleate,Methysergide Maleate,Sansert,UML-491,Dimaleate, Methysergide,Désernil Sandoz,Maleate, Methysergide,UML 491,UML491
D008813 Mice, Inbred ICR An inbred strain of mouse that is used as a general purpose research strain, for therapeutic drug testing, and for the genetic analysis of CARCINOGEN-induced COLON CANCER. Mice, Inbred ICRC,Mice, ICR,Mouse, ICR,Mouse, Inbred ICR,Mouse, Inbred ICRC,ICR Mice,ICR Mice, Inbred,ICR Mouse,ICR Mouse, Inbred,ICRC Mice, Inbred,ICRC Mouse, Inbred,Inbred ICR Mice,Inbred ICR Mouse,Inbred ICRC Mice,Inbred ICRC Mouse
D008956 Models, Chemical Theoretical representations that simulate the behavior or activity of chemical processes or phenomena; includes the use of mathematical equations, computers, and other electronic equipment. Chemical Models,Chemical Model,Model, Chemical
D009270 Naloxone A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. MRZ 2593-Br,MRZ-2593,Nalone,Naloxon Curamed,Naloxon-Ratiopharm,Naloxone Abello,Naloxone Hydrobromide,Naloxone Hydrochloride,Naloxone Hydrochloride Dihydride,Naloxone Hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Narcan,Narcanti,Abello, Naloxone,Curamed, Naloxon,Dihydride, Naloxone Hydrochloride,Hydrobromide, Naloxone,Hydrochloride Dihydride, Naloxone,Hydrochloride, Naloxone,MRZ 2593,MRZ 2593 Br,MRZ 2593Br,MRZ2593,Naloxon Ratiopharm
D009292 Narcotic Antagonists Agents inhibiting the effect of narcotics on the central nervous system. Competitive Opioid Antagonist,Narcotic Antagonist,Opioid Antagonist,Opioid Antagonists,Opioid Receptor Antagonist,Opioid Reversal Agent,Competitive Opioid Antagonists,Opioid Receptor Antagonists,Opioid Reversal Agents,Agent, Opioid Reversal,Agents, Opioid Reversal,Antagonist, Competitive Opioid,Antagonist, Narcotic,Antagonist, Opioid,Antagonist, Opioid Receptor,Antagonists, Competitive Opioid,Antagonists, Narcotic,Antagonists, Opioid,Antagonists, Opioid Receptor,Opioid Antagonist, Competitive,Opioid Antagonists, Competitive,Receptor Antagonist, Opioid,Receptor Antagonists, Opioid,Reversal Agent, Opioid,Reversal Agents, Opioid
D010146 Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS. Suffering, Physical,Ache,Pain, Burning,Pain, Crushing,Pain, Migratory,Pain, Radiating,Pain, Splitting,Aches,Burning Pain,Burning Pains,Crushing Pain,Crushing Pains,Migratory Pain,Migratory Pains,Pains, Burning,Pains, Crushing,Pains, Migratory,Pains, Radiating,Pains, Splitting,Physical Suffering,Physical Sufferings,Radiating Pain,Radiating Pains,Splitting Pain,Splitting Pains,Sufferings, Physical
D010880 Piperidines A family of hexahydropyridines.

Related Publications

Seong-Soo Choi, and Ki-Jung Han, and Jin-Koo Lee, and Han-Kyu Lee, and Eun-Jung Han, and Do-Hoon Kim, and Hong-Won Suh
July 2013, Archives of pharmacal research,
Seong-Soo Choi, and Ki-Jung Han, and Jin-Koo Lee, and Han-Kyu Lee, and Eun-Jung Han, and Do-Hoon Kim, and Hong-Won Suh
January 2013, Biological & pharmaceutical bulletin,
Seong-Soo Choi, and Ki-Jung Han, and Jin-Koo Lee, and Han-Kyu Lee, and Eun-Jung Han, and Do-Hoon Kim, and Hong-Won Suh
November 2009, Archives of pharmacal research,
Seong-Soo Choi, and Ki-Jung Han, and Jin-Koo Lee, and Han-Kyu Lee, and Eun-Jung Han, and Do-Hoon Kim, and Hong-Won Suh
October 1996, General pharmacology,
Seong-Soo Choi, and Ki-Jung Han, and Jin-Koo Lee, and Han-Kyu Lee, and Eun-Jung Han, and Do-Hoon Kim, and Hong-Won Suh
January 2003, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,
Seong-Soo Choi, and Ki-Jung Han, and Jin-Koo Lee, and Han-Kyu Lee, and Eun-Jung Han, and Do-Hoon Kim, and Hong-Won Suh
September 2010, American journal of veterinary research,
Seong-Soo Choi, and Ki-Jung Han, and Jin-Koo Lee, and Han-Kyu Lee, and Eun-Jung Han, and Do-Hoon Kim, and Hong-Won Suh
April 2018, Neuropeptides,
Seong-Soo Choi, and Ki-Jung Han, and Jin-Koo Lee, and Han-Kyu Lee, and Eun-Jung Han, and Do-Hoon Kim, and Hong-Won Suh
April 1996, Planta medica,
Seong-Soo Choi, and Ki-Jung Han, and Jin-Koo Lee, and Han-Kyu Lee, and Eun-Jung Han, and Do-Hoon Kim, and Hong-Won Suh
August 2021, Naunyn-Schmiedeberg's archives of pharmacology,
Seong-Soo Choi, and Ki-Jung Han, and Jin-Koo Lee, and Han-Kyu Lee, and Eun-Jung Han, and Do-Hoon Kim, and Hong-Won Suh
March 2011, Archives of pharmacal research,
Copied contents to your clipboard!